Video

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non—small cell lung cancer (NSCLC).

B-F1RST is a single-arm trial assessing a novel blood-based tumor mutational burden (TMB) marker in patients with NSCLC who are receiving single-agent atezolizumab (Tecentriq) in the frontline setting. TMB is an important and emerging area in the use of checkpoint inhibitor therapy, Kim says. PD-L1 is used as a biomarker for checkpoint inhibitor therapy right now, and while it has clinical utility, many feel that there is room for more biomarkers. A blood-based TMB marker was explored in this trial.

Patients were treated with atezolizumab until progression or lack of clinical benefit. TMB was assessed at baseline. The blood that was submitted had to have a minimum amount of tumor cell content in order for those patients to be evaluated, Kim explains.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity